Epidemiology from Literature | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | 1.1 - Asymptomatic | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 10.460 | 20101214, Gadisseur R
| 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 21.980 | 20100301, Scala E
| 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 34.200 | 20131020, van Rhijn BD
| 1.11 - Esophagitis, Diagnosed | 2014 | Spain | IgE | 67 | 10.500 | 20140625, Armentia A
| 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 51.430 | 20130605, Simon D
| 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 26.040 | 20120528, Patelis A
| 1.4 - Respiratory Symptoms, Diagnosed | 2012 | France | IgE | 129 | 23.300 | 20121204, Caimmi D
| 1.4 - Respiratory Symptoms, Diagnosed | 2014 | Italy | IgE | 21 | 76.200 | 20141114, Costa C
| 1.4 - Respiratory Symptoms, Diagnosed | 2013 | Spain | IgE | 187 | 19.300 | 20131016, Feliu A
| 1.4 - Respiratory Symptoms, Diagnosed | 2011 | Spain | IgE | 68 | 45.600 | 20110509, Rodriguez D
| 1.4 - Respiratory Symptoms, Diagnosed | 2008 | Spain | IgE | 786 | 28.750 | 20081010, Barber D
| 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 27.140 | 20130111, Ott H
| 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 40.000 | 20091005, Ott H
| 1.9 - Pollen Allergy | 2014 | Czech Republic | IgE | 826 | 44.700 | 20140606, Panzner P
| 1.9 - Pollen Allergy | 2014 | Spain | IgE | 50 | 12.000 | 20140625, Armentia A
| 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 3.700 | 20110223, De Knop KJ
| 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 3.850 | 20091121, Ebo DG
| 3.1.1 - Source Sensitized (SPT) | 2003 | Italy | IgE | 749 | 50.300 | 2003, Mari A
| 3.1.1 - Source Sensitized (SPT) | 2001 | Italy | IgE | 367 | 56.400 | 2001a, Rossi RE
| 3.1.4 - Source Sensitized (SPT, IgE) | 2001 | Italy | IgE | 77 | 72.700 | 2001a, Rossi RE
| 3.2.1 - Source Sensitized (IgE) | 2003 | Austria | IgE | 25 | 100.000 | 2003a, Westritschnig K
| 3.2.1 - Source Sensitized (IgE) | 2005 | Finland | IgE | 57 | 60.000 | 20041224, Moverare R
| 3.2.1 - Source Sensitized (IgE) | 2005 | Finland | IgE | 12 | 0.000 | 20041224, Moverare R
| 3.2.1 - Source Sensitized (IgE) | 1998 | Netherlands | IgE | 154 | 55.200 | 1998, van Ree R
| 3.2.1 - Source Sensitized (IgE) | 2003 | Zimbabwe | IgE | 25 | 27.000 | 2003a, Westritschnig K
| 4.1.3 - Heterologous Source Sensitized (SPT) | 2013 | Italy | IgE | 18 | 88.880 | 20131031, Bonura A
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Austria | IgE | 54 | 46.300 | 20120310, Twaroch TE
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 22.730 | 20091121, Ebo DG
| 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Italy | IgE | 26 | 46.200 | 20120310, Twaroch TE
| 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 80.000 | 20091121, Ebo DG
| 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Austria | IgE | 32 | 19.000 | 20090211, Constantin C
| 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Austria | IgE | 22 | 41.000 | 20090211, Constantin C
| 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 37.830 | 20090826, Ebo DG
| 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 233 | 10.800 | 20120726, Flores E
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Austria | IgE | 29 | 93.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Canada | IgE | 15 | 67.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Denmark | IgE | 26 | 92.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | France | IgE | 38 | 68.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Japan | IgE | 20 | 45.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 103 | 62.800 | 20141003, Beitia JM
| 5.2.1 - Source Exposed (Symptoms, SPT) | 2011 | Spain | IgE | 43 | 69.800 | 20110713, Cabrera-Freitag P
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Sweden | IgE | 35 | 63.000 | 1996, Laffer S
| 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Switzerland | IgE | 20 | 60.000 | 1996, Laffer S
| 5.2.4 - Source Exposed, Adults (Symptoms, IgE) | 2012 | Czech Republic | IgE | 48 | 79.100 | 20120424, Sekerkova A
| 5.2.5 - Source Exposed, Children (Symptoms, IgE) | 2012 | Czech Republic | IgE | 82 | 59.800 | 20120424, Sekerkova A
| 5.2.5 - Source Exposed, Children (Symptoms, IgE) | 2014 | Spain | IgE | 55 | 58.180 | 20140618, Cases B
| 5.3.1 - Source Exposed (Symptoms, IgE) | 1994 | Austria | IgE | 30 | 70.000 | 1994, Laffer S
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 43.430 | 20110223, De Knop KJ
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Germany | IgE | 101 | 81.190 | 20140306, Darsow U
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 37 | 30.000 | 20140127, Konradsen JR
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 28 | 32.000 | 20140127, Konradsen JR
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 57.000 | 20131014, Bokanovic D
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 55.100 | 20131014, Bokanovic D
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 51.000 | 20131014, Bokanovic D
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2009 | Austria | IgE | 17 | 88.000 | 20090211, Constantin C
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Austria | IgE | 82 | 73.100 | 20080314, Westritschnig K
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2000 | Italy | IgE | 276 | 59.400 | 2000, Rossi RE
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Austria | SPT | 82 | 71.950 | 20080314, Westritschnig K
| 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 5.930 | 20120528, Patelis A
|
|